United Kingdom Endocrinology Rare Disease Drugs Market Insight
United Kingdom Endocrinology Rare Disease Drugs Market is growing at an 15.6% CAGR, driven by rare endocrine disorders, orphan drug development, NHS initiatives, biologics, diagnostics, and precision medicine adoption.
United Kingdom Endocrinology Rare Disease Drugs Market Insights Forecasts to 2035
- The United Kingdom Endocrinology Rare Disease Drugs Market Size Was Estimated at USD 10.01 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 15.6% from 2025 to 2035
- The United Kingdom Endocrinology Rare Disease Drugs Market Size is Expected to Reach USD 42.67 Billion by 2035
Notable Insights for United Kingdom Endocrinology Rare Disease Drugs Market
- By drug type, hormone replacement and biologic therapies dominated, accounting for approximately 63% share in 2024, driven by increasing treatment demand for adrenal and pituitary disorders.
- By indication, congenital adrenal hyperplasia and hypoparathyroidism therapies dominated, holding approximately 39% share, supported by growing diagnosis rates and expanded NHS rare disease management programs.
- Approximately 5% of the UK population is affected by rare diseases, with endocrine-related rare disorders representing a clinically significant treatment segment requiring specialized therapies.
Download the eBook (ToC)
- Around 70% of diagnosed patients receive long-term orphan drug therapies through hospital-based endocrine and rare disease treatment centers across the United Kingdom.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Endocrinology Rare Disease Drugs Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Endocrinology Rare Disease Drugs Market
- Pfizer
- Novartis
- Recordati Rare Diseases
- Ascendis Pharma
- Novo Nordisk
- Takeda Pharmaceutical Company
- AbbVie
- Ipsen
- Others
Recent Developments:
- In August 2025, the MHRA approved teplizumab (Tzield) in the UK for delaying Stage 3 Type 1 diabetes onset in patients aged eight years and older through immunotherapy.
- In April 2025, Eli Lilly reported positive Phase 3 results for oral GLP-1 agonist orforglipron, highlighting its potential as a convenient tablet alternative to injectable endocrine and metabolic therapies.
Market Segmentation:
United Kingdom Endocrinology Rare Disease Drugs Market, By Drug Type
- Hormone Replacement Therapies
- Biologic Therapies
- Gene-Based Therapies
- Enzyme Replacement Therapies
- Others
United Kingdom Endocrinology Rare Disease Drugs Market, By Indication
- Congenital Adrenal Hyperplasia
- Hypoparathyroidism
- Cushing’s Syndrome
- Acromegaly
- Rare Pituitary Disorders
- Others
United Kingdom Endocrinology Rare Disease Drugs Market, By End User
- Hospitals & Clinics
- Specialty Endocrinology Centers
- Rare Disease Treatment Centers
- Research Institutes
United Kingdom Endocrinology Rare Disease Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Endocrinology Rare Disease Drugs Market is projected to exhibit robust growth owing to growing awareness regarding rare endocrine disorders, better diagnostic techniques for genetics, and expansion of NHS Orphan Diseases program. Biologic and hormone replacement drugs have proven themselves as the most effective for treating chronic conditions and hence are expected to dominate the market in future. The rapid development in the area of targeted drug development, precision medicines, and gene therapy will further contribute towards future growth until 2035.